Samsung Bioepis Co., Ltd. has received marketing approval in Japan for Ustekinumab BS Subcutaneous Injection 45mg Syringes ‘NIPRO’, a biosimilar referencing Johnson & Johnson’s Stelara. Developed by Samsung Bioepis and licensed for commercialization through its domestic partner Nipro Corporation, the biosimilar has been approved for the treatment of plaque psoriasis and psoriatic arthritis. The product is expected to be commercially launched following its listing on Japan’s National Health Insurance (NHI) drug price list in May 2026.

Why Japan’s approval of Samsung Bioepis’ ustekinumab marks a shift in biosimilar strategy for Asia

Japan has traditionally taken a conservative stance toward biosimilar adoption, but rising health expenditures, a rapidly aging population, and pressure to manage pharmaceutical budgets have begun shifting policy and prescriber sentiment. With approximately 10 percent of Japan’s GDP allocated to healthcare, one of the highest rates among Organisation for Economic Co-operation and Development nations, the national healthcare system is under increasing fiscal strain. Biosimilars offer a compelling cost-containment mechanism, especially for biologics such as ustekinumab that command high prices due to their role in treating chronic autoimmune conditions.

The regulatory approval of Samsung Bioepis’ ustekinumab biosimilar under the Nipro alliance signals a new chapter in biosimilar commercialization strategy in Asia. Rather than launching independently or through multinational distributors, Samsung Bioepis is pursuing deeper local market integration via a trusted domestic partner. Nipro Corporation’s brand recognition and established distribution networks in Japan are likely to enhance prescriber confidence and enable more efficient uptake upon reimbursement activation.

This strategy, while not entirely new, reflects a growing recognition that biosimilar success in Asian markets may depend more on local infrastructure alignment than on global regulatory velocity. The Japanese Ministry of Health, Labour and Welfare has generally supported biosimilar expansion, but uptake varies significantly across therapeutic areas. With this approval, Samsung Bioepis has positioned itself to not only participate in but help shape the next phase of Japan’s biosimilar landscape.

What makes this approval clinically and commercially significant for Samsung Bioepis

Ustekinumab is a monoclonal antibody that inhibits interleukin-12 and interleukin-23 signaling pathways, making it a critical therapy for immune-mediated inflammatory diseases. Its reference product, Stelara, has been a top-selling biologic worldwide, with annual revenues exceeding USD 9 billion before biosimilar erosion began in select markets. While several biosimilar developers have targeted the molecule, relatively few have succeeded in gaining approval in major markets across multiple continents.

Samsung Bioepis already markets its ustekinumab biosimilar in countries including the United States, Canada, the United Kingdom, Switzerland, Australia, Brazil, and South Korea. The Japan approval expands that global footprint and affirms the consistency of the biosimilar’s regulatory performance. Industry analysts suggest that achieving approval in Japan, which has traditionally applied high standards to biologic equivalence, is an important validation of both the manufacturing and clinical development processes underpinning the product.

The decision to launch with a 45mg pre-filled syringe format aligns with Japanese delivery preferences and treatment regimens for chronic autoimmune conditions. However, it is notable that the current approval scope does not include Crohn’s disease or ulcerative colitis, two additional indications for which ustekinumab has significant market value in other geographies. Whether Samsung Bioepis and Nipro will pursue label expansion in Japan remains an open question.

Why Nipro’s involvement may reshape biosimilar commercialization playbooks

While the approval itself is a milestone, the deeper story lies in the partnership between Samsung Bioepis and Nipro Corporation. Nipro brings an in-country credibility that is difficult to replicate with foreign-led commercialization efforts. In markets like Japan, physician trust is often closely tied to familiarity with the company behind the product, not just the regulatory stamp of approval.

Nipro’s ability to navigate hospital procurement channels, engage clinicians through educational outreach, and execute sales operations tailored to Japanese workflows could prove decisive in accelerating uptake. Regulatory watchers note that this model stands in contrast to previous biosimilar launches in Japan, where overseas manufacturers struggled to overcome entrenched originator loyalty and the opacity of institutional purchasing dynamics.

Samsung Bioepis’ decision to pair scientific rigor with local operational capability may signal a broader strategic shift in how it approaches emerging biosimilar markets. If successful, this template could be replicated in other high-barrier countries across Southeast Asia and Latin America, where healthcare systems often resist foreign encroachment without domestic buy-in.

What market dynamics could still hinder biosimilar success despite approval

While regulatory approval is a critical step, it does not guarantee commercial traction. Japan’s biosimilar policies allow for prescriber discretion, and substitution at the pharmacy level is not mandated for biologics. This creates a slower conversion dynamic, particularly in specialties such as dermatology and rheumatology, where long-standing familiarity with the originator can delay switching.

Moreover, the May 2026 timeline for inclusion in the National Health Insurance drug price list means that Samsung Bioepis will not generate revenue from the product for at least several months. This delay creates an opening for competitors. Other biosimilar developers, including Alvotech, Amgen, and Celltrion, have ustekinumab programs that may reach the Japanese market within a similar time window, increasing the risk of price erosion and formulary dilution.

In addition, reimbursement rules in Japan are often tied to hospital group purchasing agreements. Without aggressive contract negotiation and alignment with procurement norms, even approved biosimilars may remain underutilized. Industry observers caution that while Samsung Bioepis and Nipro have a favorable regulatory foundation, success will ultimately depend on the precision of post-approval execution.

What this development suggests about the future of immunology biosimilars in Japan

Immunology remains one of the highest-growth segments for biosimilars globally, yet it is also among the most resistant to change in Japan. Unlike oncology or nephrology, where treatment is protocol-driven and procurement centralization is more advanced, autoimmune care involves greater physician discretion and patient continuity concerns.

The approval of a high-profile immunology biosimilar like ustekinumab could serve as a bellwether for broader systemic change. If Samsung Bioepis and Nipro can demonstrate sustained uptake, supported by real-world evidence and favorable pricing, it may open the door for future approvals of biosimilars targeting tumor necrosis factor-alpha and interleukin-17, two additional cytokine pathways heavily used in dermatology and rheumatology.

Regulators may also use the May 2026 listing as a litmus test for refining their biosimilar incentive structure. Whether through increased provider education, patient co-pay adjustments, or risk-sharing models, Japan’s Ministry of Health, Labour and Welfare may adjust its policies depending on how this biosimilar performs in-market.

How Samsung Bioepis is positioning itself for regional biosimilar leadership

Samsung Bioepis’ success across multiple geographies reflects a shift from biosimilar volume toward biosimilar value. In the past, being first to market was often seen as the primary competitive advantage. Today, the focus has evolved toward integrated go-to-market models, regulatory agility, and scalable partnerships.

With its Nipro-led Japan launch, Samsung Bioepis is signaling its intent to become a regionally embedded player, not just a global manufacturer with licenses. This could have long-term implications for the firm’s standing in high-barrier markets such as China, Indonesia, and Malaysia, where trust, infrastructure, and local co-development increasingly determine commercial success.

If the ustekinumab launch proceeds smoothly and achieves real-world adoption, Samsung Bioepis will have demonstrated that biosimilar success in Asia requires more than just manufacturing muscle. It requires localization, strategic humility, and a willingness to collaborate with established players in-market. That model could become the industry’s new benchmark.

  Asian biopharma, autoimmune, biologics, biosimilar, biosimilar approval, drug pricing, immunology, Japan, NHI, Nipro Corporation, psoriasis, psoriatic arthritis, Samsung Bioepis, Stelara, ustekinumab